Table 2 Summary of the treatment and outcome
ID | Study | Primary surgery (IRS) | Secondary surgery | CT | Response | RT (Gy) | Relapse | Outcome |
|---|---|---|---|---|---|---|---|---|
1 | CWS-96 | Resection (R2, III) | Re-resection (R1) | VAIA | PTR | 30.4 | LR | DOD |
2 | CWS-96 | Resection (R2, III) | Re-resection (R1) | VAIA | PTR | 44.8 | NED | |
3 | CWS-96 | Open biopsy (R2, III) | Resection (R0) | CEVAIE Trofosfamid/VP16 Trofosfamid/Idarubicin SCT | SD | NED | ||
4 | CWS-96 | Resection (R2, III) | VAIA/VACA | PTR | 39.6 | NED | ||
5 | CWS-96 | ERCP biopsy (R2, III) | CEVAIE + maintenance therapy Vinblastin/Cyclofosfamide | CR | NED | |||
6 | CWS-96 | Open biopsy (R2, III) | VAIA | GR | 24 | LR | NED | |
7 | CWS-96 | Resection (R1, II) | VAIA | PTR | 36 | LR | NED | |
8 | CWS-96 | Open biopsy (R2, III) | Resection (R1) | VAIA | PR | 32.4 | NED | |
9 | CWS-96 | Open biopsy (R2, III) | CEVAIE + SCT | CR | 44 | CR | DOD | |
10 | CWS-96 | Open biopsy (R2, III) | CEVAIE + OTIE | PD | PD | DOD | ||
11 | CWS-2002P | Open biopsy (R2, III) | VAIA | GR | 30.6 | NED | ||
12 | CWS-2002P | ERCP biopsy (R2, III) | Resection (R0) | I2VA | GR | CR | DOD | |
13 | CWS-2002P | Open biopsy (R2, III) | Resection (R0) | VAIA | Nos | LR | DOD | |
14 | SoTiSaR | Open biopsy (R2, III) | Resection (R0) | CEVAIE | SD | NED | ||
15 | SoTiSaR | ERCP biopsy (R2, III) | Resection (R0) | CEVAIE+OTIE | CR | NED | ||
16 | SoTiSaR | Resection (R0, I) | VA | PTR | NED | |||
17 | SoTiSaR | Open biopsy (R2, III) | CEVAIE + OTIE | PD | PD | DOD |